{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:14:30Z","timestamp":1789791270926,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2025-02292969"],"award-info":[{"award-number":["RS-2025-02292969"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10120-026-01755-6","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:00:39Z","timestamp":1779440439000},"page":"816-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic implications of tissue-based homologous recombination deficiency in metastatic gastric cancer treated with immune checkpoint inhibitor plus chemotherapy"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5759-727X","authenticated-orcid":false,"given":"Changgon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Mee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok Geun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"1755_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"1755_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1186\/s12916-024-03801-5","volume":"22","author":"X Zhang","year":"2024","unstructured":"Zhang X, Dai X, Liu A, Sun M, Cong L, Liang J, et al. Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study. BMC Med. 2024;22:585. https:\/\/doi.org\/10.1186\/s12916-024-03801-5.","journal-title":"BMC Med"},{"key":"1755_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","volume":"27","author":"MD Stewart","year":"2022","unstructured":"Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N, et al. Homologous recombination deficiency: concepts, definitions, and assays. Oncologist. 2022;27:167\u201374. https:\/\/doi.org\/10.1093\/oncolo\/oyab053.","journal-title":"Oncologist"},{"key":"1755_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/jco.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol. 2023;41:609\u201317. https:\/\/doi.org\/10.1200\/jco.22.01549.","journal-title":"J Clin Oncol"},{"key":"1755_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/jco.23.00339","volume":"42","author":"J Mateo","year":"2024","unstructured":"Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial. J Clin Oncol. 2024;42:571\u201383. https:\/\/doi.org\/10.1200\/jco.23.00339.","journal-title":"J Clin Oncol"},{"key":"1755_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","volume":"184","author":"ME Robson","year":"2023","unstructured":"Robson ME, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 2023;184:39\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2023.01.031.","journal-title":"Eur J Cancer"},{"key":"1755_CR7","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.18632\/aging.202267","volume":"13","author":"P Zhou","year":"2020","unstructured":"Zhou P, Wu X, Chen H, Hu Y, Zhang H, Wu L, et al. The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses. Aging (Albany NY). 2020;13:2365\u201378. https:\/\/doi.org\/10.18632\/aging.202267.","journal-title":"Aging (Albany NY)"},{"key":"1755_CR8","doi-asserted-by":"publisher","first-page":"973","DOI":"10.4143\/crt.2020.798","volume":"53","author":"HY Wang","year":"2021","unstructured":"Wang HY, Deng L, Li YQ, Zhang X, Long YK, Zhang X, et al. Pan-cancer analysis of tumor mutational burden and homologous recombination DNA damage repair using targeted next-generation sequencing. Cancer Res Treat. 2021;53:973\u201382. https:\/\/doi.org\/10.4143\/crt.2020.798.","journal-title":"Cancer Res Treat"},{"key":"1755_CR9","doi-asserted-by":"publisher","first-page":"826577","DOI":"10.3389\/fimmu.2022.826577","volume":"13","author":"SB Silva","year":"2022","unstructured":"Silva SB, Wanderley CWS, Colli LM. Immune checkpoint inhibitors in tumors harboring homologous recombination deficiency: Challenges in attaining efficacy. Front Immunol. 2022;13:826577. https:\/\/doi.org\/10.3389\/fimmu.2022.826577.","journal-title":"Front Immunol"},{"key":"1755_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092249","author":"S van Wilpe","year":"2021","unstructured":"van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, et al. Homologous recombination repair deficiency and implications for tumor immunogenicity. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13092249.","journal-title":"Cancers (Basel)"},{"key":"1755_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/po.17.00286","author":"AL Heeke","year":"2018","unstructured":"Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol. 2018. https:\/\/doi.org\/10.1200\/po.17.00286.","journal-title":"JCO Precis Oncol"},{"key":"1755_CR12","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s00432-021-03781-6","volume":"148","author":"H Kim","year":"2022","unstructured":"Kim H, Ahn S, Kim H, Hong JY, Lee J, Park SH, et al. The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. J Cancer Res Clin Oncol. 2022;148:2427\u201335. https:\/\/doi.org\/10.1007\/s00432-021-03781-6.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1755_CR13","doi-asserted-by":"publisher","first-page":"102595","DOI":"10.1016\/j.ctrv.2023.102595","volume":"119","author":"R T\u00e9bar-Mart\u00ednez","year":"2023","unstructured":"T\u00e9bar-Mart\u00ednez R, Mart\u00edn-Arana J, Gimeno-Valiente F, Tarazona N, Rentero-Garrido P, Cervantes A. Strategies for improving detection of circulating tumor DNA using next generation sequencing. Cancer Treat Rev. 2023;119:102595. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102595.","journal-title":"Cancer Treat Rev"},{"key":"1755_CR14","doi-asserted-by":"publisher","first-page":"33614","DOI":"10.18632\/oncotarget.16833","volume":"8","author":"AW Hahn","year":"2017","unstructured":"Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, et al. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget. 2017;8:33614\u201320. https:\/\/doi.org\/10.18632\/oncotarget.16833.","journal-title":"Oncotarget"},{"key":"1755_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051379","author":"I Labiano","year":"2023","unstructured":"Labiano I, Huerta AE, Arrazubi V, Hernandez-Garcia I, Mata E, Gomez D, et al. State of the art: ctDNA in upper gastrointestinal malignancies. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15051379.","journal-title":"Cancers (Basel)"},{"key":"1755_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cjp2.271","volume":"8","author":"J Budczies","year":"2022","unstructured":"Budczies J, Kluck K, Beck S, Ourailidis I, Allg\u00e4uer M, Menzel M, et al. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types. J Pathol: Clin Res. 2022;8:371\u201382. https:\/\/doi.org\/10.1002\/cjp2.271.","journal-title":"J Pathol: Clin Res"},{"key":"1755_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152436","author":"JE Shin","year":"2025","unstructured":"Shin JE, Kwon M, Lim SH, Hong JY, Kim ST. The impact of DDR gene mutations on the efficacy of Etoposide plus Cisplatin in grade 3 metastatic gastroenteropancreatic (GEP)-neuroendocrine carcinoma (NEC). Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17152436.","journal-title":"Cancers (Basel)"},{"key":"1755_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.Cd-17-0226","volume":"7","author":"KW Mouw","year":"2017","unstructured":"Mouw KW, Goldberg MS, Konstantinopoulos PA, D\u2019Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7:675\u201393. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0226.","journal-title":"Cancer Discov"},{"key":"1755_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23:239-54.e6. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.076.","journal-title":"Cell Rep"},{"key":"1755_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature24673","volume":"552","author":"G Germano","year":"2017","unstructured":"Germano G, Lamba S, Rospo G, Barault L, Magr\u00ec A, Maione F, et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature. 2017;552:116\u201320. https:\/\/doi.org\/10.1038\/nature24673.","journal-title":"Nature"},{"key":"1755_CR21","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.Cd-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10:1808\u201325. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0522.","journal-title":"Cancer Discov"},{"key":"1755_CR22","doi-asserted-by":"publisher","first-page":"1599908","DOI":"10.3389\/fimmu.2025.1599908","volume":"16","author":"F Sun","year":"2025","unstructured":"Sun F, Gao X, Wang W, Zhao X, Zhang J, Zhu Y. Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives. Front Immunol. 2025;16:1599908. https:\/\/doi.org\/10.3389\/fimmu.2025.1599908.","journal-title":"Front Immunol"},{"key":"1755_CR23","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.20892\/j.issn.2095-3941.2020.0089","volume":"17","author":"Y Fan","year":"2020","unstructured":"Fan Y, Ying H, Wu X, Chen H, Hu Y, Zhang H, et al. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. Cancer Biol Med. 2020;17:1002\u201313. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0089.","journal-title":"Cancer Biol Med"},{"key":"1755_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010311","author":"DR Gandara","year":"2025","unstructured":"Gandara DR, Agarwal N, Gupta S, Klempner SJ, Andrews MC, Mahipal A, et al. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010311.","journal-title":"J Immunother Cancer"},{"key":"1755_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00280-018-3652-2","volume":"82","author":"K Yamaguchi","year":"2018","unstructured":"Yamaguchi K, Kusaba H, Makiyama A, Mitsugi K, Uchino K, Tamura S, et al. The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. Cancer Chemother Pharmacol. 2018;82:625\u201333. https:\/\/doi.org\/10.1007\/s00280-018-3652-2.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1755_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1001\/jamaoncol.2022.7136","volume":"9","author":"E Rassy","year":"2023","unstructured":"Rassy E, Le Roy F, Smolenschi C, Val\u00e9ry M, Boige V, Ducreux M, et al. Rechallenge after oxaliplatin-induced hypersensitivity reactions. JAMA Oncol. 2023;9:434\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7136.","journal-title":"JAMA Oncol"},{"key":"1755_CR27","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3892\/or.2014.3080","volume":"31","author":"Y Nakagawa","year":"2014","unstructured":"Nakagawa Y, Kajihara A, Takahashi A, Kondo N, Mori E, Kirita T, et al. The BRCA2 gene is a potential molecular target during 5-fluorouracil therapy in human oral cancer cells. Oncol Rep. 2014;31:2001\u20136. https:\/\/doi.org\/10.3892\/or.2014.3080.","journal-title":"Oncol Rep"},{"key":"1755_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1158\/1078-0432.Ccr-22-0931","volume":"29","author":"KN Chi","year":"2023","unstructured":"Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, et al. Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound. Clin Cancer Res. 2023;29:81\u201391. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-0931.","journal-title":"Clin Cancer Res"},{"key":"1755_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115522","author":"A Cimadamore","year":"2021","unstructured":"Cimadamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, et al. Circulating tumor DNA testing for homology recombination repair genes in prostate cancer: from the lab to the clinic. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22115522.","journal-title":"Int J Mol Sci"},{"key":"1755_CR30","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/2159-8290.Cd-20-1408","volume":"11","author":"DVT Catenacci","year":"2021","unstructured":"Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, et al. Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a Phase II study evaluating an individualized treatment strategy for metastatic disease. Cancer Discov. 2021;11:308\u201325. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1408.","journal-title":"Cancer Discov"},{"key":"1755_CR31","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41467-017-00921-w","volume":"8","author":"N Riaz","year":"2017","unstructured":"Riaz N, Blecua P, Lim RS, Shen R, Higginson DS, Weinhold N, et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nat Commun. 2017;8:857. https:\/\/doi.org\/10.1038\/s41467-017-00921-w.","journal-title":"Nat Commun"},{"key":"1755_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1186\/s12885-025-14267-w","volume":"25","author":"L Ren","year":"2025","unstructured":"Ren L, Yao R, Hou T, Liu C, Zhao F, Chen X, et al. Pan-cancer analysis of homologous recombination deficiency and homologous recombination repair-associated gene alterations in solid tumors from a large Asian cohort. BMC Cancer. 2025;25:946. https:\/\/doi.org\/10.1186\/s12885-025-14267-w.","journal-title":"BMC Cancer"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01755-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:49:14Z","timestamp":1782715754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01755-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01755-6","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are fully responsible for the content of this manuscript, and the views and opinions described in this publication are solely those of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Samsung Medical Center (approval number: [IRB NO. 2025-09-044-002]).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}